levosalbutamol hydrochloride + ipratropium bromide

Levosalbutamol hydrochloride + ipratropium bromide is a fixed-dose combination inhalation solution developed for the treatment of respiratory conditions characterized by reversible airway obstruction, such as asthma and chronic obstructive pulmonary disease (COPD). Levosalbutamol is the (R)-enantiomer of salbutamol and acts as a selective beta-2 adrenergic receptor agonist, promoting bronchodilation by relaxing airway smooth muscle. Ipratropium bromide is a non-selective muscarinic receptor antagonist that inhibits bronchoconstriction by blocking the action of acetylcholine in the airways. This combination therapy provides synergistic bronchodilatory effects by targeting two different pathways of airway narrowing. The product is being developed by Jinan Jingsheng Technology and Luoxin Anruoweita Pharmaceutical, with clinical studies characterizing its pharmacokinetic profile and safety in healthy adults.

Other names

levalbuterol hydrochloride + ipratropium bromidelevosalbutamol + ipratropiumlevalbuterol + ipratropiumlevosalbutamol hydrochloride and ipratropium bromide inhalation solutionlevalbuterol hydrochloride and ipratropium bromide inhalation solution